An option to modify the progressive course of Parkinson’s
Related Stories
21 de November de 2023
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
Posted in: Uncategorised
8 de May de 2023
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with…
Posted in: Parkinson
8 de May de 2023
The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured…
Posted in: Parkinson
16 de January de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
8 de June de 2021
The Hospital Universitari General de Catalunya, through the Clinical Research Unit (UDIC), has included the…
Posted in: News
8 de June de 2021
The Hospital Universitari General de Catalunya, which was the first center in Spain activated for…
Posted in: News